Dr. Reddy’s Laboratories has been granted a patent for pharmaceutical compositions involving 1,2,4-oxadiazole compounds, specifically designed for cancer treatment. The compositions include specific side chains and are intended for administration to subjects in need of cancer therapy. GlobalData’s report on Dr. Reddy’s Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dr. Reddy's Laboratories, Cancer treatment biomarkers was a key innovation area identified from patents. Dr. Reddy's Laboratories's grant share as of June 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using 1,2,4-oxadiazole compounds
The granted patent US12037321B2 outlines a method for treating various types of cancer, specifically targeting subjects in need of such treatment. The claims detail the administration of a compound selected for its therapeutic properties against cancer. Notably, the claims specify that the method can be applied to treat non-Hodgkin's lymphoma, leukemia, and lymphoma. The patent also encompasses variations of the compound, including its pharmaceutically acceptable salts, indicating a focus on both the active ingredient and its derivatives for effective treatment.
Further claims elaborate on the specific types of cancer that can be addressed using the identified compounds, reinforcing the versatility of the treatment method. The claims emphasize the potential for these compounds to be utilized in a clinical setting, providing a framework for their application in treating hematological malignancies. Overall, the patent presents a structured approach to cancer treatment, highlighting the importance of the selected compounds and their formulations in addressing specific cancer types.
To know more about GlobalData’s detailed insights on Dr. Reddy's Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
